SCHEMBL530112

SCHEMBL530112

CCCCc1ccccc1OC(N)=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.58
THRB P10828 1/20 0.58
PPARA Q07869 2/20 0.47
PPARG P37231 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NR1I2 O75469 1/20 0.45
LMNA P02545 1/20 0.45
CHRM2 P08172 1/20 0.45
CYP3A4 P08684 1/20 0.45
ADRA2A P08913 1/20 0.45
MAPT P10636 1/20 0.45
OPRK1 P41145 1/20 0.45
HTR2B P41595 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
PTGS2 P35354 2/20 0.44
ALOX5 P09917 1/20 0.44
KDM4E B2RXH2 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859888 1.00 THRA (0.58) THRATHRBPPARAPPARGMEN1
SCHEMBL30409234 0.95 THRA (0.65) THRATHRBPPARAPPARGMEN1
SCHEMBL1838225 0.95 THRA (0.65) THRATHRBPPARAPPARGMEN1
SCHEMBL30945776 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1
SCHEMBL30945830 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1
SCHEMBL1837003 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1
SCHEMBL30945791 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1
SCHEMBL1954643 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1
SCHEMBL1840956 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1
SCHEMBL1835734 0.94 THRA (0.68) THRATHRBPPARAPPARGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090589-A1 HETEROCYCLIC HBS1L DEGRADERS TANGO THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
EP-4698224-A1 SAPONIN DERIVATIVES AS ADJUVANTS AND PHOTOAFFINITY PROBES Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) 2026-02-25 EP disclosed
US-20250313563-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2025-10-09 US disclosed
WO-2025077996-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2025-04-17 WO disclosed
EP-4466278-A1 SAPONIN-BASED ADJUVANTS AND VACCINES Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) 2024-11-27 EP disclosed
EP-3795561-B1 METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE ASAHI CHEMICAL IND (JP) 2024-11-06 EP disclosed
WO-2024218268-A1 SAPONIN DERIVATIVES AS ADJUVANTS AND PHOTOAFFINITY PROBES ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2024-10-24 WO disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
CN-118215651-A Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition 旭化成株式会社 2024-06-18 CN disclosed
EP-2365962-A2 AMINOALCOHOL LIPIDOIDS AND USES THEREOF Massachusetts Institute of Technology (US) 2011-09-21 EP disclosed
WO-2011073970-A1 A GASTROINTESTINAL IMPLANT DEVICE VYSERA BIOMEDICAL LIMITED (IE) 2011-06-23 WO disclosed
WO-2011073967-A1 A BIOMATERIAL VYSERA BIOMEDICAL LIMITED (IE) 2011-06-23 WO disclosed
EP-2331018-A1 ESOPHAGEAL VALVE Vysera Biomedical Limited (IE) 2011-06-15 EP disclosed
US-20110133121-A1 N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-06-09 US disclosed
EP-2322504-A1 PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER Asahi Kasei Chemicals Corporation (JP) 2011-05-18 EP disclosed
WO-2010057006-A9 AZAQUINOLINONE DERIVATIVES AND USES THEREOF LINK MEDICINE CORPORATION (US) 2010-09-16 WO disclosed
WO-2010057006-A1 AZAQUINOLINONE DERIVATIVES AND USES THEREOF LINK MEDICINE CORPORATION (US) 2010-05-20 WO disclosed
WO-2010053572-A2 AMINOALCOHOL LIPIDOIDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-05-14 WO disclosed
WO-2009153770-A1 ESOPHAGEAL VALVE VYSERA BIOMEDICAL LIMITED (IE) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110133121-A1 N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound CPS1, ALKBH3, RCC1 THRA 4461/4885THRB 4723/4885PPARA 772/4885
US-20250313563-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF GSK3B, GSK3A, PYGL THRA 1413/4885THRB 625/4885PPARA 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.